Cholesterol: The good, the bad, and the ugly-therapeutic targets for the treatment of dyslipidemia

Medical Principles and Practice

Volumn 23, Issue 2, 2014, Pages 99-111

  Elshourbagy, Nabil A ^a   Meyers, Harold V ^a   Abdel Meguid, Sherin S ^a  

^a Shifa Biomedical   (United States)

Author keywords

Atherosclerosis; Cholesterol; Dyslipidemia

Indexed keywords

1D 05; ALIROCUMAB; ANACETRAPIB; ANTILIPEMIC AGENT; ATORVASTATIN; BOCOCIZUMAB; CER 001; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; ENDOTHELIAL LIPASE; EVOLOCUMAB; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LGT 209; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; MDCO 216; MEVINOLIN; MIPOMERSEN; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; PROPROTEIN CONVERTASE SUBTILISIN LIKE KEXIN TYPE 9; ROSUVASTATIN; SIMVASTATIN; SUBTILISIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; DIMER; ENDOTHELIAL LIPASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PCSK9 INHIBITOR; PEPTIDOMIMETIC AGENT; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; SERINE PROTEINASE;

AMNESIA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONSTIPATION; DIABETES MELLITUS; DISTRESS SYNDROME; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; DYSPEPSIA; GALLSTONE; GALLSTONE FORMATION; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; GOUT; HEART DISEASE; HUMAN; HYPERGLYCEMIA; LIVER INJURY; LIVER TOXICITY; MUSCLE INJURY; MYOPATHY; NAUSEA; NONHUMAN; PLEIOTROPY; PRURITUS; REVIEW; VOMITING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG TARGETING; LIPID BLOOD LEVEL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPASE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TRIGLYCERIDES;

EID: 84896126149     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000356856     Document Type: Review

References (143)

1. World Health Organization: World Health Statistics 2012. 2012. http://www.who.int/healthinfo/EN-WHS2012-Full.pdf.
2. World Health Organization: Cause-specific mortality: regional estimates for 2008. 2011. http://www.who.int/healthinfo/global-burden-disease/estimates- regional/en/index. html.
3. World Health Organization: Causes of death 2008: data sources and methods. 2011. http://www.who.int/healthinfo/global-burden-disease/cod-2008- sources-methods.pdf.
4. World Health Organization: Global health risks: mortality and burden of disease attributable to selected major risks. 2009. http://www.who.int/ healthinfo/global-burden-disease/GlobalHealthRisks-report-full.pdf.
5. Centers for Disease Control and Prevention: Heart disease and stroke prevention: addressing the nation's leading killers. 2006. http://www.cdc.gov/ nccdphp/publications/AAG/pdf/aag-dhdsp2006.pdf.
6. Centers for Disease Control and Prevention: Heart disease and stroke prevention: addressing the nation's leading killers. 2010. http://www.cdc.gov/ chronicdisease/resources/publications/aag/pdf/2010/dhdsp.pdf.
7. American Heart Association: Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood. 2003. http://www.americanheart.org/.
8. Strong JP, Malcom GT, McMahan CA, et al: Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. J Am Med Assoc 1999; 281: 7277-7235.
9. Badimon L, Vilahur G: LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. Ann NY Acad Sci 2012; 1254: 18-32.
10. Bandeali S, Farmer J: High-density lipoprotein and atherosclerosis: the role of antioxidant activity. Curr Atheroscler Rep 2012; 14: 101-107.
11. Pauwels EK: The protective effect of the Mediterranean diet: focus on cancer and cardiovascular risk. Med Princ Pract 2011; 20: 103-111.
12. Lewis GF, Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-1232. (Pubitemid 40962099)
13. Bruckert E, Baccara-Dinet M, McCoy F, et al: High prevalence of low HDL-cholesterol in a pan-European survey of 8,545 dyslipidaemic patients. Curr Med Res Opin 2005; 21: 1927-1934. (Pubitemid 41803102)
14. Aguilar-Salinas CA, Olaiz G, Valles V, et al: High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res 2001; 42: 1298-1307. (Pubitemid 32744254)
15. Wilson PW, D'Agostino RB, Levy D, et al: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847. (Pubitemid 28213628)
16. Brewer HB Jr: Increasing HDL cholesterol levels. N Engl J Med 2004; 350: 1491-1494. (Pubitemid 38477773)
17. Hausenloy DJ, Yellon DM: Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 2008; 94: 706-714. (Pubitemid 351744686)
18. Rothblat GH, Llera-Moya MD, Atger V, et al: Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 1999; 40: 781-796. (Pubitemid 29220519)
19. Yokoyama S: Apolipoprotein-mediated cellular cholesterol efflux. Biochim Biophys Acta 1998; 1392: 1-15. (Pubitemid 28291847)
20. Zannis VI, Cohen J: Old and new players in the lipoprotein system. Curr Opin Lipidol 2000; 11: 101-103. (Pubitemid 30219103)
21. Epstein SE, Zhou YF, Zhu J: Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 1999; 100:e20-e28.
22. Hessler JR, Robertson AL Jr, Chisolm GM 3rd: LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979; 32: 213-229. (Pubitemid 9129780)
23. Colles SM, Maxson JM, Carlson SG, et al: Oxidized LDL-induced injury and apoptosis in atherosclerosis: potential roles for oxysterols. Trends Cardiovasc Med 2001; 11: 131-138. (Pubitemid 33070336)
24. Boudjeltia KZ, Legssyer I, Van Antwerpen P, et al: Triggering of inflammatory response by myeloperoxidase-oxidized LDL. Biochem Cell Biol 2006; 84: 805-812. (Pubitemid 46121606)
25. Martin-Fuentes P, Civeira F, Recalde D, et al: Individual variation of scavenger receptor expression in human macrophages with oxidized low-density lipoprotein is associated with a differential inflammatory response. J Immunol 2007; 179: 3242-3248.
26. Galkina E, Ley K: Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009; 27: 165-197.
27. Murphy AJ, Woollard KJ: High density lipoprotein-a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol 2010; 37: 710-718.
28. Kontush A, Chapman MJ: Antiatherogenic small, dense HDL-guardian angel of the arterial wall Nat Clin Pract Cardiovasc Med 2006; 3: 144-153.
29. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154.
30. Stafforini DM, McIntyre TM, Prescott SM: Platelet-activating factor acetylhydrolase from human plasma. Methods Enzymol 1990; 187: 344-357. (Pubitemid 20309300)
31. Forte TM, Subbanagounder G, Berliner JA, et al: Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res 2002; 43: 477-485. (Pubitemid 34252278)
32. Navab M, Berliner JA, Subbanagounder G, et al: HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481-488. (Pubitemid 32323377)
33. Navab M, Anantharamaiah GM, Reddy ST, et al: Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opin Lipidol 2004; 15: 645-649. (Pubitemid 39612982)
34. Navab M, Hama SY, Anantharamaiah GM, et al: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-1508.
35. Jahangiri A, de Beer MC, Noffsinger V, et al: HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 2009; 29: 261-267.
36. Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58: 342-374. (Pubitemid 44394906)
37. Van Lenten BJ, Hama SY, de Beer FC, et al: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-2767.
38. Tsironis LD, Katsouras CS, Lourida ES, et al: Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis 2004; 177: 193-201. (Pubitemid 39361156)
39. Sampietro T, Neglia D, Bionda A, et al: Inflammatory markers and serum lipids in idiopathic dilated cardiomyopathy. Am J Cardiol 2005; 96: 1718-1720. (Pubitemid 41790397)
40. Khovidhunkit W, Kim M-S, Memon RA, et al: Thematic review series: the pathogenesis of atherosclerosis-effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-1196. (Pubitemid 38802622)
41. Nofer JR, Kehrel B, Fobker M, et al: HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002; 161: 1-16. (Pubitemid 34214816)
42. Nicholls SJ, Tuzcu EM, Sipahi I, et al: Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499-508. (Pubitemid 46220805)
43. Thomson Micromedex: Niacin. http://www. thomsonhc.com (accessed June 16, 2008).
44. Thomson Micromedex: Gemfibrozil. http://www.thomsonhc.com (accessed June 16, 2008).
45. Inukai Y, Ito K, Hara K, et al: Serum cholesteryl ester transfer protein concentrations are associated with serum levels of total cholesterol, beta-lipoprotein and apoproteins in patients with type 2 diabetes mellitus. Med Princ Pract 2007; 16: 367-372. (Pubitemid 47294492)
46. Joy TR, Hegele RA: The failure of torcetrapib: what have we learned Br J Pharmacol 2008; 154: 1379-1381.
47. Husten L: Roche terminates development of CETP inhibitor dalcetrapib. Forbes, May 7, 2012.
48. National Institutes of Health: AIM-HIGH trial (NCT00120289). 2011. www.clinicaltrials. gov.
49. American Heart Association: RTP-UPDATE 2-US study doubting niacin's heart effects challenged. 2011. http://www.reuters.com/article/2011/11/17/heart- niacin/idUSN1E7AG1JC20111117.
50. Jaye M, Lynch K, Krawiec J, et al: A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 1999; 21: 424-428. (Pubitemid 29159582)
51. McCoy MG, Sun GS, Marchadier D, et al: Characterization of the lipolytic activity of endothelial lipase. J Lipid Res 2002; 43: 921-929. (Pubitemid 34602614)
52. Ma K, Cilingiroglu M, Otvos JD, et al: Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci USA 2003; 100: 2748-2753. (Pubitemid 36297570)
53. Ishida T, Choi S, Kundu RK, et al: Endothelial lipase is a major determinant of HDL level. J Clin Invest 2003; 111: 347-355. (Pubitemid 36182211)
54. Hara T, Ishida T, Kojima Y, et al: Targeted deletion of endothelial lipase increases HDL particles with anti-inflammatory properties both in vitro and in vivo. J Lipid Res 2011; 52: 57-67.
55. Yasuda T, Ishida T, Rader DJ: Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J 2010; 74: 2263-2270.
56. Otera H, Ishida T, Nishiuma T, et al: Targeted inactivation of endothelial lipase attenuates lung allergic inflammation through raising plasma HDL level and inhibiting eosinophil infiltration. Am J Physiol Lung Cell Mol Physiol 2009; 296:L594-L602.
57. Yasuda T, Hirata K, Ishida T, et al: Endothelial lipase is increased by inflammation and promotes LDL uptake in macrophages. J Atheroscler Thromb 2007; 14: 192-201.
58. Ishida T, Choi S, Kundu R, et al: Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. J Biol Chem 2004; 279: 45085-45092. (Pubitemid 39430923)
59. Jin W, Millar JS, Broedl U, et al: Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest 2003; 111: 357-362. (Pubitemid 36182212)
60. Hutter CM, Austin MA, Farin FM, et al: Association of endothelial lipase gene (LIPG) haplotypes with high-density lipoprotein cholesterol subfractions and apolipoprotein AI plasma levels in Japanese Americans. Atherosclerosis 2006; 185: 78-86.
61. Badellino KO, Wolfe ML, Reilly MP, et al: Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med 2006; 3:e22.
62. Cox L, Birnbaum S, Mahaney M, et al: Identification of promoter variants in baboon endothelial lipase that regulate high-density lipoprotein cholesterol levels. Circulation 2007; 116: 1185-1195. (Pubitemid 47360220)
63. Winkler F, D'Arcy A, Hunziker W: Structure of human pancreatic lipase. Nature 1990; 343: 771-774.
64. Goodman KB, Bury MJ, Cheung M, et al: Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. Bioorg Med Chem Lett 2009; 19: 27-30.
65. Choi SY, Hirata K, Ishida T, et al: Endothelial lipase: a new lipase on the block. J Lipid Res 2003; 43: 1765-1769.
66. O'Connell DP, LeBlanc DF, Cromley D, et al: Design and synthesis of boronic acid inhibitors of endothelial lipase. Bioorg Med Chem Lett 2012; 22: 1397-1401.
67. Brousseau ME, Kauffman RD, Herderick EE, et al: LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits. Arterioscler Thromb Vasc Biol 2000; 20: 450-458. (Pubitemid 30086103)
68. Furbee JW Jr, Sawyer JK, Parks JS: Lecithin: cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem 2002; 277: 3511-3519. (Pubitemid 34953221)
69. Sorci-Thomas MG, Thomas MJ: The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 2002; 12: 121-128. (Pubitemid 34462182)
70. Lowe ME: The triglyceride lipases of the pancreas. J Lipid Res 2002; 43: 2007-2016.
71. Sarda L: Pancreatic lipase; in Alberghina L, Schmid R, Verger R (eds): Lipases: Structure Mechanism and Genetic Engineering. New York, Springer, 1991.
72. Peelman F, Vinaimont N, Verhee A, et al: A proposed architecture for lecithin cholesterol acyl transferase (LCAT): identification of the catalytic triad and molecular modeling. Protein Sci 1998; 7: 587-599. (Pubitemid 28130880)
73. Ollis DL, Cheah E, Cygler M, et al: The alpha/beta hydrolase fold. Protein Eng 1992; 5: 197-211.
74. Francone OL, Fielding CJ: Structure-function relationships in human lecithin:cholesterol acyltransferase: site-directed mutagenesis at serine residues 181 and 216. Biochemistry 1991; 30: 10074-10077.
75. Anantharamaiah GM, Mishra VK, Garber DW, et al: Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 2007; 48: 1915-1923. (Pubitemid 47360611)
76. Chen X, Burton C, Song X, et al: An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration. Int J Biol Sci 2009; 5: 489-499.
77. Tanigawa H, Billheimer JT, Tohyama J, et al: Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation 2009; 120: 160-169.
78. Hovingh GK, de Groot E, van der Steeg W, et al: Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 2005; 16: 139-145. (Pubitemid 40515887)
79. Scarpioni R, Paties C, Bergonzi G: Dramatic atherosclerotic vascular burden in a patient with familial lecithin-cholesterol acyltransferase (LCAT) deficiency. Nephrol Dial Transplant 2008; 23: 1074, author reply 1074-1075. (Pubitemid 351767582)
80. Calabresi L, Favari E, Moleri E, et al: Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis 2009; 204: 141-146.
81. Jonas A: Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000; 1529: 245-256.
82. Miida T, Zhang B, Obayashi K, et al: T13M mutation of lecithin-cholesterol acyltransferase gene causes fish-eye disease. Clin Chim Acta 2004; 343: 201-208. (Pubitemid 38534517)
83. Mertens A, Verhamme P, Bielicki JK, et al: Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003; 107: 1640-1646. (Pubitemid 36397333)
84. Duivenvoorden R, Holleboom AG, van den Bogaard B, et al: Cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging. J Am Coll Cardiol 2011; 58: 2481-2487.
85. Duivenvoorden R, Holleboom AG, van den Bogaard B, et al: Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging (corrected). J Am Coll Cardiol 2012; 59: 196.
86. Van Craeyveld E, Lievens J, Jacobs F, et al: Apolipoprotein A-I and lecithin:cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesions. Gene Ther 2009; 16: 757-765.
87. Chen Z, Wang SP, Krsmanovic ML, et al: Small molecule activation of lecithin cholesterol acyltransferase modulates lipoprotein metabolism in mice and hamsters. Metabolism 2012; 61: 470-481.
88. Franceschini G, Sirtori CR, Capurso A, et al: A-IMilano apoprotein: decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980; 66: 892-900. (Pubitemid 11233787)
89. Cerenis Therapeutics: CER-001 (Cerenis HDL). http://cerenis.com/pipeline- cer001. asp.
90. Bloedon L, Dunbar R, Duffy D, et al: Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in highrisk cardiovascular patients. J Lipid Res 2008; 49: 1344-1352.
91. Kaul S, Shah PK: ApoA-I Milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progression. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 471-479. (Pubitemid 43008520)
92. The Medicine Company: Pipeline. http://www.themedicinescompany.com/page/ pipeline.
93. Keyserling CH, Hunt TL, Klepp HM, et al: CER-001, a synthetic HDL-mimetic, safely mobilizes cholesterol in healthy dyslipidemic volunteers (abstract). Circulation 2011; 124:A15525.
94. Navab M, Anantharamaiah GM, Reddy ST, et al: Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005; 25: 1325-1331.
95. Anantharamaiah GM, Mishra VK, Garber DW, et al: Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 2007; 48: 1915-1923. (Pubitemid 47360611)
96. Navab M, Anantharamaiah GM, Reddy ST, et al: Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 2006; 3: 540-547. (Pubitemid 44445797)
97. Ozasa H, Ayaori M, Iizuka M, et al: Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPAR/LXR pathway: findings from in vitro and ex vivo studies. Atherosclerosis 2011; 219: 141-150.
98. Talbert RL: Hyperlipidemia; in DiPiro JT, Talbert RL, Yee GC, et al (eds): Pharmacotherapy: a Pathophysiologic Approach, ed 6. New York, McGraw-Hill, 2005.
99. Malloy MJ, Kane JP: Agents used in hyperlipidemia; in Katzung BG (ed): Basic and Clinical Pharmacology, ed 9. New York, McGraw-Hill, 2004, pp 561-575.
100. National Institutes of Health, National Heart, Lung, and Blood Institute: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) executive summary. NIH Publication 01-3670. Bethesda, NIH, 2001.
101. Graham DJ, Staffa JA, Shatin D, et al: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-2590. (Pubitemid 39577514)
102. United States Food and Drug Administration: FDA expands advice on statin risk. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm.
103. HDL LDL Cholesterol: Lowering Cholesterol Drugs Information On Their Effects. http://www.cholesterol-hdl-ldl.com/lowering-cholesterol-drugs.html.
104. WebMD: High cholesterol: cholesterollowering medication. http://www.webmd. com/cholesterol-management/guide/cholesterol-lowering- medication.
105. American Heart Association: Drug therapy for cholesterol. http://www.heart.org/HEARTORG/Conditions/Cholesterol/ PreventionTreatmentofHighCholesterol/D r u g-T h e r a p y-f o r-C h o l e s t e r o l-UCM-305632-Article.jsp.
106. Kotani K, Sakane N, Taniguchi N: Effect of ezetimibe on remnant-like particle cholesterol in subjects with metabolic syndrome. Med Princ Pract 2012; 21: 134-138.
107. Pearson TA, Laurora I, Chu H, et al: The lipid treatment assessment project (LTAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-467. (Pubitemid 30112269)
108. Steinberg D, Witztum J: Inhibition of PCSK9: a powerful weapon for achieving ideal cholesterol levels. Proc Natl Acad Sci USA 2009; 106: 9546-9547.
109. Piper D, Jackson S, Liu Q, et al: The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 2007; 15: 545-552. (Pubitemid 46702689)
110. Naureckiene S, Ma L, Sreekumar K, et al: Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys 2003; 420: 55-67. (Pubitemid 37393374)
111. Abifadel M, Varret M, Rabes J, et al: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-156. (Pubitemid 36666925)
112. Basak A: Inhibitors of proprotein convertases. J Mol Med 2005; 83: 844-855. (Pubitemid 41598685)
113. Benjannet S, Rhainds D, Essalmani R, et al: NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004; 279: 48865-48875. (Pubitemid 39625767)
114. Benjannet S, Rhainds D, Hamelin J, et al: The proprotein convertase PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 2006; 281: 30561-30572. (Pubitemid 44582112)
115. Cunningham D, Danley DE, Geoghegan KF, et al: Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007; 14: 413-419. (Pubitemid 46685885)
116. Pisciotta L, Priore Oliva C, Cefalu AB, et al: Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis 2006; 186: 433-440.
117. Maxwell K, Breslow J: Adenoviral-mediated expression of PCSK9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 2004; 101: 7100-7105. (Pubitemid 38596449)
118. Cohen J, Pertsemlidis A, Kotowski I, et al: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37: 161-165.
119. Rashid S, Curtis D, Garuti R, et al: Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci USA 2005; 102: 5374-5379. (Pubitemid 40530265)
120. Zhao Z, Tuakli-Wosornu Y, Lagace T, et al: Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79: 514-523. (Pubitemid 44384260)
121. Li J, Tumanut C, Gavigan J-A, et al: Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J 2007; 406: 203-207. (Pubitemid 47310950)
122. McNutt MC, Lagace TA, Horton JD: Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 2007; 282: 20799-20803. (Pubitemid 47099894)
123. Zhang D-W, Lagace TA, Garuti R, et al: Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007; 282: 18602-18612. (Pubitemid 47100234)
124. Kwon HJ, Lagace TA, McNutt MC, et al: Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 2008; 105: 1820-1825. (Pubitemid 351439423)
125. Bottomley MJ, Cirillo A, Orsatti L, et al: Structural and biochemical characterization of the wild type PCSK9/EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem 2009; 284: 1313-1323.
126. Seidah NG: PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets 2009; 13: 19-28.
127. Seidah NG, Prat A: The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012; 11: 367-383.
128. Graham MJ, Lemonidis KM, Whipple CP, et al: Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007; 48: 763-767. (Pubitemid 46557881)
129. Lindholm MW, Elmen J, Fisker N, et al: PCSK9 RNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 2012; 20: 376-381.
130. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al: Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008; 105: 11915-11920.
131. Seidah N, Benjannet S, Wickham L, et al: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1) liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003; 100: 928-933. (Pubitemid 36183932)
132. McNutt MC, Kwon HJ, Chen C, et al: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 2009; 284: 10561-10570.
133. Cohen J, Boerwinkle E, Mosley TH, et al: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-1272.
134. Duff CJ, Scott MJ, Kirby IT, et al: Antibodymediated disruption of the interaction between PCSK9 and the low density lipoprotein receptor. Biochem J 2009; 419: 577-584.
135. Chan JCY, Piper DE, Cao Q, et al: A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009; 106: 9820-9825.
136. Liang H, Chaparro-Riggers J, Strop P, et al: Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther 2012; 340: 228-236.
137. Dias C, Shaywitz A, Smith B, et al: A phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability and pharmacodynamics of AMG145 (abstract). Circulation 2011; 124:A10701.
138. Kohli P, Desai NR, Giugliano RP, et al: Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebocontrolled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol 2012; 35: 385-391.
139. Stein EA, Mellis S, Yancopoulos GD, et al: Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-1118.
140. McKenney J, Koren M, Kereiakes D, et al: Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012; 59: 2344-2353.
141. Sullivan D, Olsson AG, Scott R, et al: Effect of a monoclonal antibody to PCSK9 on lowdensity lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308: 2497-2506.
142. Aegerion Pharmaceuticals Announces Oral Presentation of Phase III Lomitapide Data at European Atherosclerosis Society Conference. 2012. http://www.aegerion.com/.
143. Genzyme: Genzyme and Isis announce FDA approval of KYNAMRO TM (mipomersen sodium) injection for the treatment of homozygous familial hypercholesterolemia. http://news.genzyme.com/pressrelease/genzyme-and-isis- announce-fdaapproval-kynamro-mipomersen-sodiuminjection-treatment-h.